Shanyang Benghuan low molecular weight heparin sodium series
source:Silk Road Dialogue Committee|Release time:2021-07-08|Number of views:
Project content: build a low molecular weight heparin purification and processing line in Shanyang industrial concentration area (east of Jingsi Road), with an annual output of 800 billion units of low molecular weight heparin sodium, which is used to produce enoxaparin sodium injection, daparin sodium injection, natroparin calcium injection, heparin sodium cream, heparin sodium blood collection and other products. At the same time, the use of pig gall, pig hair, pig pancreas and other raw materials to extract bilirubin, amino acids, insulin and other drugs more than 5000 kg. The project covers an area of 150 mu (about 100000 square meters), including 66000 square meters of building base area, 15000 square meters of road and site hardening area, and 19000 square meters of green space.
Total investment and cooperation mode: the total investment of the project is 1 billion yuan. Among them, the construction investment is 880 million yuan, the interest during the construction period is 57 million yuan, and the initial working capital is 63 million yuan. The funds are raised by enterprises themselves, bank loans and national special funds, including 350 million yuan raised by enterprises themselves and 650 million yuan obtained by banks and national special funds. Cooperation mode: joint venture, cooperation or other.
Market forecast and investment return analysis: as one of the most widely used and effective anticoagulant and antithrombotic drugs, heparin drugs occupy an important position in the international pharmaceutical market with huge market space and broad development prospects. After the completion of the project, the annual sales revenue will be 1.2 billion yuan, the profit will be 300 million yuan and the tax will be 75 million yuan. It can promote 500 employees and bring remarkable economic and social benefits.